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According to the authors and editors, this report contains the most justified principles of diagnostic and therapeutic 
procedures prepared considering the scientific value of evidence and category of recommendations. These principles 
should always be interpreted in the context of an individual clinical situation. The recommendations do not always 
correspond to the current reimbursement rules in Poland. In case of doubt, the current possibilities of reimbursement 
of individual procedures should be established.
1.  The quality of scientific evidence
 I — Scientific evidence obtained from well-designed and conducted randomized clinical trials or meta-analyses of 
randomized clinical trials
 II — Scientific evidence obtained from well-designed and conducted prospective observational studies (non-randomized 
cohort studies)
 III — Scientific evidence obtained from retrospective observational studies or case-control studies
 IV — Scientific evidence obtained from clinical experiences and/or experts, opinions
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2.  Category of recommendations
 A — Indications confirmed unambiguously and absolutely useful in clinical practice
 B — Indications probable and potentially useful indications in clinical practice
 C — Indications determined individually
Correct diagnosis and effective combination therapy 
of primary malignant bone tumours (bone sarcomas) 
depend on the cooperation of radiologists and nuclear 
medicine specialists, pathologists, surgical oncologists 
and orthopaedic surgeons, medical oncologists, ra-
diotherapists, and physiotherapists. Multidisciplinary 
treatment should necessarily be carried out in the cen-
tres of the respective experiment (III, A). Multi-centre 
cooperation is recommended within the framework of 
the Polish Bone Cancer Registry (prnk@coi.waw.pl). 
The introduction of combined treatment allows five-year 
survival in approximately 60–70% of patients and in-
creases the percentage of patients in whom the limb 
can be preserved.
Epidemiology and aetiology
Bone sarcomas in adults are a diverse group of tu-
mours of mesenchymal origin. They are rare, constitut-
ing less than 0.5% of new cases of all malignancies. In 
some cases, detailed histogenesis is unknown.
Clinically, bone sarcomas are divided into spindle 
cell and small cell. Osteosarcoma occurs most often 
among spindle-cell sarcomas — in Poland diagnosed 
annually in approximately 60–100 people (2–3 per 
1,000,000), and more common in men (1.4 to 1) and 
young people (approx. 80% of cases in second and 
third decade and about 20% of cases in the sixth and 
seventh decades of life). The second most common 
in the incidence of spindle-bone sarcomas in adults is 
chondrosarcoma, and others (e.g. fibrosarcoma or undif-
ferentiated pleomorphic sarcoma) are much rarer. Small 
cell sarcomas (e.g. Ewing’s sarcoma or mesenchymal 
chondrosarcoma) occupy the third spot in the incidence 
of primary malignant bone tumours in adults. However, 
in the first and second decade of life, Ewing’s sarcoma is 
second — after osteosarcoma — in terms of prevalence 
(3 cases per 1,000,000; about 40–60 cases per year) of 
primary malignant bone tumour (in about half of the 
patients between 10 and 20 years old, children under 
five years of age rarely, boys more often).
A small number of spindle cell sarcomas occur on 
the basis of predisposing diseases (e.g. Paget’s disease 
or hereditary retinoblastoma  — osteosarcoma, multiple 
osteochondral osteomas — chondrosarcoma) or may be 
induced by previous irradiation. Small cell sarcomas do 
not develop secondary to other conditions and do not 
occur in familial or hereditary cancer syndromes [1, 2].
Bone sarcomas in children and adolescents are 
7–8.2% of all cancers in this age group. Annually about 
75 new cases are diagnosed in Poland. The most fre-
quently diagnosed is osteosarcoma — 56% of all bone 
tumours in children and adolescents (approximately 
40 new cases per year), followed by Ewing sarcoma 34% 
(approximately 25 new cases per year). Other, much less 
frequent malignant bone tumours in children are chon-
drosarcoma and fibrosarcoma. In rare cases, the skeleton 
may also be the primary location of lymphoma [3, 4]. 
Primary bone lymphoma is not discussed in this paper.
Diagnostics
Medical history and physical examination
The most important and early symptom is pain, 
which is usually stronger at night and gradually increases 
in the following months of the disease (the exception 
being the majority of chondrosarcomas). In the later 
stages of the disease there may be observed a tumour 
and distortion of the limb — the symptoms are con-
nected by some of the patients with trauma (in fact, the 
injury only draws attention to the disease, but does not 
cause cancer). About 40% of small cell sarcomas have 
a so-called inflammatory mask (symptoms of inflamma-
tion and fever), which makes proper diagnosis difficult. 
In about 60% of patients at the time of diagnosis there 
is soft tissue infiltration. Bone sarcomas are often ac-
companied by limb dysfunctions (limited mobility of 
the nearest joint with reflex saving) and permanent 
articular contractures and bone fractures in cases of lo-
cal advancement. The diagnosis of early forms of bone 
sarcomas (volume less than 100 cm3 and no crossing of 
the cortical bone) is very difficult and usually accidental. 
In the more advanced local stage of small cell sarcoma, 
general symptoms (fever, anaemia, weakness) may oc-
cur, which — apart from increased activity of lactate de-
hydrogenase (LDH) — are negative prognostic factors.
Osteosarcoma is most often located near the meta-
physes of the long bones — mainly the distal femoral area 
(around the knee area — about 50%), the proximal part 
of the tibia or brachial bone, and the head of the fibula 
bone. Osteosarcoma develops most often on the basis 
of healthy and fast-growing bone (young people), but it 
can also arise at the site of previous benign lesions (e.g. 
fibrous dysplasia, bone infarction, or — in older people 
— Paget’s disease). Chondrosarcomas occur more often 
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later in life and often affect differently shaped bones 
(pelvis, shoulder girdle) or proximal femur and can de-
velop from pre-existing lesions (e.g. osteochondroma or 
enchondroma). Ewing sarcomas most often concern the 
shaft of long or flat bones, spine, and pelvis.
Imaging studies
The first and basic study is an X-ray of the entire 
bone in two projections together with the adjacent joint 
(classic forms of bone sarcoma give symptoms charac-
teristic of each type of sarcoma).
In the group of small cell tumours, X-ray images are 
often atypical, especially in the early stages of the dis-
ease and in small children. The tumour usually destroys 
healthy bones through osteolytic defects or infiltration. 
Sometimes there are signs of pathological malignancy 
of calcified (bone or cartilage) tissue and malignant 
periosteal reactions (e.g. Codman’s triangle or spikulae). 
In children and adolescents in Ewing sarcoma osteolysis 
foci are visible and sometimes sclerotic changes coex-
ist. Periosteum reactions that can run parallel to the 
bones are very typical (image of “onion skins”). It is 
not uncommon for a bone fracture to coexist (around 
15%). Depending on the type of sarcoma and the rate of 
tumour growth, infiltration can pass to the growth plate, 
and also damage to joint cartilage can occur.
In further diagnostics (assessment of the local stage 
of the cancer by determining the extent of changes in soft 
tissues and seizing the bony layer and spongy bone), mag-
netic resonance imaging (MRI) is helpful to visualise bone 
marrow, joints, and attitudes to surrounding structures, 
as well as computed tomography (CT). Bone scans help 
to exclude lesions in other parts of the skeleton. In the 
assessment of the stage of small cell sarcomas, it may be 
helpful to perform a positron emission tomography (PET) 
examination together with a CT scan (PET-CT). It is al-
ways necessary to perform a chest X-ray examination to 
exclude metastases (metastases in the lungs — about 20% 
of patients at the time of diagnosis of bone sarcoma) [5–7].
Pathomorphological assessment
Histological diagnosis is established on the basis 
of tissue examination of the material from the surgi-
cal biopsy or oligobiopsy. It is important to choose the 
place of material collection (based on the assessment 
of the surgeon and pathologist made on the basis of full 
diagnostic procedure), which should contain tumour 
cells intact necrotic. The place of material collection 
should be removed during the final excision by one 
group of doctors. In Ewing sarcomas in adults, bone 
marrow retrieval should be considered for histological 
examination, which in about 15% of patients contains 
cancer cells; in children, bone marrow examination is 
part of the compulsory testing before starting treatment.
The basic method of biopsy in bone sarcomas is an 
open biopsy, and only a part of experienced centres base 
on the examination of material obtained by trepanobio-
psy or core-needle biopsy (in children and adolescents, 
the method of choice is an open biopsy). Biopsy incision 
should not interfere with subsequent surgery and leads 
to unfavourable expansion of irradiation fields and in-
creases the risk of pathological fracture. The residual 
activity of the isotope (99Tc) given during bone scinti - 
graphy can be used to select the best site and determine it 
intraoperatively using a manual (sterile) gamma-camera. 
Incisions for the open biopsy and for subsequent radical 
excision must coincide (scar after an open biopsy — an 
inseparable fragment of the pathological preparation). 
A biopsy should be performed away from the neurovas-
cular bundle. When choosing a biopsy site the results 
of X-ray and bone scintigraphy need to be used and 
the principle of the shortest path between the skin and 
the tumour should be applied. A skin incision — long 
enough to reach deeply situated lesions — should be 
carried out in parallel to the long axis of the limb. Dur-
ing preparation, the limits of the muscle compartment 
should not be exceeded. The specimen from the tumour 
infiltration should be taken “sharply” from the periphery 
(the largest proliferation and the smallest necrosis). 
In tumours without crossing the cortical layer of long 
bones, one should cut the bone window in the thinnest 
place, in order not to weaken the bones and promote 
a pathological fracture. During the removal of the speci-
men, significant bleeding from the tumour may occur. 
Thorough haemostasis should be performed within the 
soft tissues and bones (e.g. wax). The wound should be 
thoroughly closed after drain removal (without drain-
age or with drainage — in this case the drain should be 
placed in the immediate vicinity of the biopsy wound), 
so as not to leave dead spaces (stitching of subsequent 
layers of muscle, fascia, subcutaneous tissue, and skin). 
It is also good practice to perform a smear on the slide 
from the collected slice to perform a cytological exami-
nation or tissue impression of a roller obtained during 
a thick-needle biopsy for the intraoperative evaluation 
of the material in terms of “diagnostics” and the ap-
propriate volume for the proper examination. In case of 
bleeding lesions the tumour mass of the material taken 
by the surgeon may constitute the necrotic part of the 
tumour. Material from bone cancer should be submitted 
for pathological examination without fixation, while in 
the case of planned molecular testing with nucleic acid 
isolation, the material should be frozen at a temperature 
of at least –70°C. Consideration should also be given to 
collecting material for microbiological testing in order 
to exclude osteoarthritis. The protection of the material 
for molecular research is currently in force in children 
and adolescents with bone tumours.
The pathomorphological report should be based 
on the classification of the World Health Organisation 
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Nonetheless, in order to plan treatment it is neces-
sary to obtain information on histological diagnosis, 
local range, and stage of the tumour (locally advanced 
or metastatic).
The standards of pathomorphological reports in-
cluding data from morphological, immunohistochemi-
cal, and molecular studies have been developed by the 
College of American Pathologists (CAP) and the Royal 
College of Pathologists (RCPath) (https://www.rcpath.
org/resourceLibrary/dataset-for-histopathology-reports 
-on-primary-bone-tumours.html); Protocol for the 
examination of cancer patients (Cancer protocol tem-
plates: www.cap.org).
Differentiation
The first stage of differentiation — using X-ray 
— includes the exclusion of benign tumours and fi-
brous dysplasia and changes in the course of metabolic 
diseases (e.g. hyperparathyroidism). Differentiation of 
the aneurysmal bone cyst is difficult because the lesion 
can be secondary to fast-growing malignant bone cancer.
The next step is the histological differentiation of 
bone sarcoma based on the examination of the material 
obtained via an open biopsy. In the differentiation of 
sarcomas, the location is of secondary value (most often 
— the metaphyseal region in spindle cell sarcomas and 
bone stems in small cell sarcomas). The importance of 
sarcoma differentiation is due to the fact that spindle 
cell tumours are insensitive to irradiation. It is impor-
tant to exclude bone lymphomas because they do not 
require surgical treatment. Metastasis of other cancers 
to the bone are more common than primary sarcomas, 
and in the differentiation the age of the patients is of 
additional importance (sarcomas are more common in 
younger people). In children and adolescents, all small 
cell malignancies of childhood (neuroblastoma, lym-
phoma, rhabdomyosarcoma, primitive neuroectodermal 
tumour, and small cell osteosarcoma) should be included 
in the differentiation.
In cases of osteosarcomas and Ewing’s sarcomas 
the assessment of material after tumour resection or 
amputation involves the analyses of the proportion of 
cross-sectional area covered by the tumour tissue necro-
sis. The prognosis is better if necrosis accounts for 90% 
or more of tumour formation.
Staging
The basis for the classification of clinical stage 
is the assessment of a group of the most important 
prognostic factors, which include: histological ma-
lignancy, neoplastic infiltration through the cortical 
bone, size of the primary tumour, and condition 
(metastases) in distant organs (mainly lungs) and 
regional lymph nodes.
Table 1. Classification of primary malignant bone tumours 
according to the World Health Organisation (WHO)
Osteogenic tumours
Osteosarcoma
Conventional osteosarcoma
 Chondroblastic subtype
 Fibroblastic subtype
 Osteoblastic sclerosing subtype
Telangiectatic osteosarcoma
Small cell osteosarcoma 
Central low-grade
Secondary osteosarcoma
Parosteal osteosarcoma
Periosteal osteosarcoma 
High-grade surface osteosarcoma
Chondrogenic tumours
Chondrosarcoma 
 Central, primary and secondary 
 Peripheral
 Dedifferentiated
 Mesenchymal
 Clear cell 
Fibrogenic tumours
Fibrosarcoma of the bone
Haemopoietic neoplasms
Plasma cell myeloma*
Primary non-Hodgkin lymphoma of the bone*
Osteoclastic giant cell rich tumours
Malignant giant cell tumour 
Notochordal tumours
Chordoma
Vascular tumours
Angiosarcoma
Epithelioid haemangioendothelioma
Myogenic tumours
Leiomyosarcoma
Lipogenic tumours
Liposarcoma
Miscellaneous tumours
Ewing sarcoma
Undifferentiated high-grade pleomorphic sarcoma of the bone
Adamantinoma
*Myeloma and primary bone lymphoma are not discussed in this paper
(WHO) (Tab. 1) [8], and in the differential diagnosis 
of small cell tumours, the availability of immunohisto-
chemistry and cytogenetic tests for the assessment of 
characteristic translocations is necessary.
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Table 2. Staging of bone sarcomas according to TNM 
classification
Primary tumour (T)
Tx Tumour cannot be assessed
T0 No sign of the tumour
T1 Tumour 8 cm or less in greatest dimension
T2 Tumour more than 8 cm in greatest dimension
T3 Discontinuous tumours in the primary bone 
site “skipping metastases”
Regional lymph nodes (N)
Nx Lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastases (M)
Mx Distant metastases cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Lung
M1b Other distant sites
Additional markings in the TNM classification
— pT (m) NM — “m” defines the presence of several tumour 
foci in one location
— rTNM — “r” defines the material that is the recurrence of 
a previously diagnosed tumour (after remission)
— ypTNM — “y” determines the material that is evaluated 
after or during chemotherapy, radiotherapy or both methods
Histology grade (G)
Gx Grade cannot be assessed
G1 Well differentiated — low grade
G2 Moderately differentiated — low grade
G3 Poorly differentiated — high grade
G4* Undifferentiated — high grade
*Ewing sarcoma — G4
Table 3. Clinical staging of bone sarcomas according to the AJCC 2010 classification
T N M G
IA
IB
T1
T2, T3
N0 M0 G1, G2 (low grade)
IIA
IIB
T1
T2
N0 M0 G3, G4 (high grade)
III T3 N0 M0 G3, G4
IVA
IVB
Any T
Any T
N0
N1
Any N
M1a
Any M
M1b
Gx–G4 (any grade)
Determination of the stage of bone sarcoma is based 
on the TNM classification according to the American 
Joint Committee on Cancer (AJCC) of 2010 (Tab. 2, 3) 
with histological malignancy (G1–G4), primary tumour 
(T1–T3), regional lymph nodes (N), and distant organ 
metastases (M) [9]. In 2018, the eight edition of UICC-
-AJCC classification was introduced, in which bone 
sarcomas located in the pelvic bones and in the spine 
are classified separately.
Treatment
All primary malignant bone tumours should be 
treated in multidisciplinary teams (IV, A), because over 
70% of bone sarcomas require combination therapy 
[especially osteosarcomas and small cell sarcomas (I, A)] 
involving — primarily — surgical treatment and che-
motherapy (Tab. 4) [1, 2, 6, 7, 10]. The primary goal is 
to obtain local control of the sarcoma through proper 
surgical radical treatment. The decision about the extent 
of this type of therapy should be made prior to initiation 
of combination therapy, and patients should agree to the 
planned extent of surgical excision before starting the 
initial chemotherapy (CTH). In the case of bone fracture 
before treatment, internal anastomoses are contraindi-
cated due to the risk of local sarcoma cell shedding and 
disqualification from the limb-saving surgery.
In terms of treatment strategies, bone sarcomas can 
be divided into four basic groups: osteosarcomas and 
other, less frequent, spindle cell sarcomas, chondro-
sarcoma, small cell sarcomas and giant cell tumours 
of bone.
When deciding on the treatment of spindle cell 
sarcoma patients (mainly osteosarcoma) and small cell 
sarcomas, the following principles apply [1, 2, 6, 7, 10]:
 — obtaining a reliable histological diagnosis before 
starting treatment;
 — the use of combined treatment within the estab-
lished therapeutic protocols (I, A), because they 
are high grade histological malignancy (results of 
exclusive surgical treatment are poor — less than 
20% of five-year survival) beside of low grade pa-
rosteal osteosarcoma (subject of discussion — use 
of peri-operative CTH in patients with spindle cellar 
sarcomas over 50 years of age) — if possible, treat-
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Table 4. General principles of treatment for particular types of bone sarcomas
Preoperative 
chemotherapy
Surgical treatment Radiotherapy Postoperative 
chemotherapy
Osteosarcoma
Other spindle cell sarcomas
Yes Yes No Yes
Chondrosarcoma* No Yes No No
Ewing sarcoma (small cell sarcomas) Yes Yes Yes Yes
Giant cell tumour No** Yes Yes No
*Excluding mesenchymal and dedifferentiated subtypes, for which the schemes as for small cell sarcomas and osteosarcoma are used, respectively; **except 
for denosumab used to optimise resection
ment should be offered to patients under prospective 
clinical trials;
 — decision about the extent of excision before com-
mencement of combination therapy — patients 
should agree to planned surgery before starting 
preoperative CTH, because the effectiveness of 
initial treatment may cause unwarranted hopes of 
avoiding amputation or surgical treatment (lack of 
knowledge, understanding, and acceptance by the 
patient of initial surgical decisions lead to conflict 
and resignation from the proposed operation, which 
is the basis for treatment and cure of the patient);
 — absence — standard — radiation therapy (RTH) in 
the radical treatment of osteosarcoma (II, A); 
 — patients with resectable metastases are treated ac-
cording to similar principles as patients with localised 
tumour, although the prognosis is significantly worse. 
In the treatment plan, if possible, include dissection 
of metastases;
 — use of three-stage procedures for the most common 
malignant bone tumours in children and adolescents:
•	 stage I — initial CTH to reduce the primary 
tumour focus and destroy micrometastases 
(4–16 weeks depending on the CTH regimen 
used and the response to treatment — EUR-
AMOS in osteosarcoma and EWING 2008 in 
Ewing sarcoma);
•	 stage II — treatment of the primary tumour (sur-
gical and/or irradiation depending on the type 
of sarcoma, location of the lesion and age of the 
patient) — the principle of removing the tumour 
with a margin of unaltered tissues applies (radical 
treatment in the histopathological assessment 
with the aspiration to preserve the limb — if 
possible — and completing the resulting defect 
with bone graft, endoprosthesis, or other form of 
reconstruction) and applying irradiation under 
the conditions of the planned three-dimensional 
conformal RTH (the possibility of using higher 
doses of targeted radiation in a shorter time and 
a significant reduction of the risk of complica-
tions — a dose of 40–65 cGy depending on the 
tolerance of tissues affected by irradiation and 
age of the patient);
•	 stage III — postoperative CTH to increase the 
chance of cure [4–8 months depending on the 
type of tumour — treatment regimen depends 
on the response to initial CTH including the 
clinical response and the degree of necrosis in 
the excised tumour — with a favourable response 
(high degree of necrosis [11]) drugs from stage I 
are used, whereas in the unfavourable case 
— new CTH regimens with the use of other drugs 
should be used; in Ewing sarcoma in children and 
adolescents in case of poor response to initial 
CTH or in the case of multiple metastatic disease 
foci, consolidation of treatment with high-dose 
CTH followed by transplantation of stem cells 
taken from the patient during the first stage of 
treatment can be applied; in the case of tumour 
progression, it is necessary to change the scheme 
and/or earlier treatment of the primary tumour].
Surgical treatment
Greater efficiency of diagnostics, introduction of 
combination therapy principles, and technological prog-
ress have resulted in extending the indications for the use 
of treatment with the possibility of saving limbs. Surgical 
sparing treatment must provide a radical local excision 
of the tumour (R0 — microscopically without infiltration 
in the surgical incision line), cannot reduce the time free 
from relapse, and must result in better functional effects 
than after amputation and external prosthesis without 
deterioration of quality of life. Limb-sparing surgeries 
should only be planned when a stabilisation or partial re-
sponse is obtained after the initial CTH. Possibilities of 
maintaining good limb fitness include: absence of pain, 
deep and superficial sensation, and limb functionality 
(upper limb — preservation of at least a grip function of 
the hand, lower limb — preserving the support function 
and the ability to walk). Indications for surgical sparing 
treatment in children and adolescents are determined 
taking into account the type of sarcoma (histological 
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diagnosis), the response to initial CTH, the anatomic 
location of the lesion, the location of the tumour biopsy, 
ratio to surrounding tissues and structures (blood vessels 
and nerves), age, and lifestyle.
Surgical procedure consists of three elements: 
tumour resection, bone reconstruction, soft tissue cov-
erage.
Tumour should be removed with the periphery of 
completely unchanged tissues after the separation of 
vascular-nerve bunches. Along with the tumour, the 
scar should be removed after the biopsy and — if pos-
sible — the tumour should be removed outside the joint. 
The most frequently used forms of reconstruction are:
 — tumour excision with subsequent joint immobilisation;
 — excision of the tumour with enucleation in the joint 
and reconstruction with the help of an endoprosthe-
sis or bone graft;
 — extra-articular tumour excision with bone recon-
struction graft.
Finally, the most difficult step in the surgical treat-
ment is to supplement the resulting loss of soft tissue. 
Various techniques of reconstruction and microsurgery 
are used, enabling the movement of the muscle or 
skin-muscle flaps (e.g. the dislocation of the gastrocne-
mius muscle), which is particularly useful for extensive 
lesions in the proximal part of the lower leg (tibia).
The type of reconstruction performed depends on: 
size and location of the tumour, age and activity of the 
patient, as well as the knowledge and experience of the 
operating team.
The analysis of the test results and the response to 
the initial CTH allows us to determine the maximum 
tumour coverage and to determine the planned extent 
of excision with the necessary margin of normal bone. 
If, despite the extent of excision, the limb or its basic 
function can be preserved, the type of reconstruction 
should be determined taking into account the location 
of the tumour and the age of the patient (in this it is 
necessary to compare the calendar age with the bone age 
defined in the wrist X-ray). If there is a high probability 
of further growth of the patient and the table prediction 
of growth and the net body height percentile calculation 
indicates that the patient will grow more than 4 cm, it 
is indication for reconstruction with implantation of 
growing, expandalbe endoprostheses enabling extension 
of the extremity. Due to the need to continue CTH in 
the post-operative period, reduced immunity, and the 
possibility of infectious complications, a non-invasive, 
electromagnetic system that does not require operation-
al intervention is preferred. In the remaining patients, 
a modular system (cementless) is used.
Implantation of the oncological endoprosthesis is as-
sociated with the possibility of complications throughout 
the patient’s life, leading even to the need for amputa-
tion of the limb. The basic problems are maintaining the 
mechanical efficiency of endoprostheses and preventing 
bone atrophy in the vicinity of the endoprosthesis. In 
some cases, it is not necessary to replace the removed 
part of the bone (e.g. pelvic or shoulder girdle surgery). 
Sometimes, in addition to the reconstruction of bone 
fragments, reconstructions in the field of muscular 
ligamentous and sometimes also vascular structures are 
necessary. If there is no possibility of radical excision 
using limb-saving methods, it is necessary to perform 
amputation (Tab. 5) at the correct level (above the 
joint and proximally from the bone involved). Surgi-
cal treatment remains the only method of treatment 
in chondrosarcoma (exception — mesenchymal and 
dedifferentiated subtype). 
Some patients with metastatic bone sarcomas 
(mainly — M1a) have a chance to be cured under the 
condition of proper association of CTH with radical 
surgical treatment of metastases provided that adequate 
local control of the tumour is obtained.
Combination therapy
Spindle cell sarcomas
Spindle cell sarcomas (mainly osteosarcoma and 
chondrosarcoma) primarily require surgical treatment 
to control the disease locally. In cases of osteosarcoma, 
regardless of localisation, it is necessary to attach 
a complementary CTH before and after surgery (I, B) 
[schemes involving doxorubicin, cisplatin, ifosfamide, 
and methotrexate (I, A)] to improve survival without 
lung metastases and overall survival (Fig. 1) [1, 2, 
5–7, 10, 12–17], and in the treatment of subsequent 
lines, ifosfamide with etoposide or gemcitabine with 
docetaxel (II, A) [18, 19] are used. Spindle-cell sarco-
mas usually are resistant to irradiation. Prognosis of 
patients with spindle cell sarcomas varies depending 
on the grade of histological malignancy and response 
to initial CTH, but overall five-year survival is around 
70% or more on the condition of proper diagnosis 
and treatment.
The high degree of histological malignancy of 
osteosarcoma in children and young adults makes it 
Table 5. Contraindications for sparing surgery in bone 
sarcomas
Failure to use initial chemotherapy in osteosarcoma and small 
cell sarcomas
The lack of an adequate response to initial chemotherapy 
(stabilisation and/or partial response)
Extensive infiltration of soft tissues and vascular-nervous structures
Pathological bone fracture (relative contraindication)
Poor placement of an open biopsy
Inability to follow-up after treatment
Complications after endoprosthesis implantation
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necessary to use combined treatment with preoperative 
and postoperative CTH and surgical treatment (RTH 
is not used in radical treatment and is only used in the 
group of young patients under palliative procedure). The 
condition of starting the treatment is histological verifi-
cation. Currently, there is no attempt to initially excise 
the tumour, which is most often associated with the need 
to perform a mutilating procedure (amputations or enu-
cleation of the limb in the joint) and does not improve 
long-term results. The most important prognostic factors 
at the time of diagnosis include: size and location of the 
tumour, histological grade, and presence or absence of 
metastases. The size of the tumour correlates with the 
activity of LDH and alkaline phosphatase, and the find-
ing of the concentration values of these enzymes consti-
tuting a multiple of the norm is a factor of poor prognosis 
(similarly as a significant size) [1, 10, 17]. Patients with 
limb localisation and distal tumour localisation have 
the best prognosis. Worse prognosis concerns patients 
with sarcomas located in the vertebrae and in the pelvic 
bones, where practically no radical resection is possible 
and attempts are being made to use protonotherapy 
(proton beam radiotherapy). The presence of metasta-
ses at the time of diagnosis of osteosarcoma is another 
factor of poor prognosis. The chance of getting a total 
cure in these patients depends among other things on the 
location and number of lesions, as well as the possibility 
of their radical resection (single metastasis — better 
prognosis, and multiple bilateral metastases — worse 
prognosis). The worst prognoses are for patients with 
dissemination to bones (rarely at the time of diagnosis) 
and to the brain (exceptionally at the beginning of the 
disease, more often with subsequent relapses). Currently, 
the most important prognostic factors are determined 
after excision of the tumour — non-radical resection 
and a low degree of tumour necrosis after initial CTH 
(more than 90% necrotic cells changed — better prog-
nosis compared with 10% or more “live” cells — poor 
prognosis). The chance of five-year survival for a group 
with a favourable prognosis is 75–80% in contrast to the 
group with poor prognosis, in which 45–55% of patients 
survive for five years.
Management of adult patients with osteosarcoma be-
gin with 3–4 cycles of preoperative CTH (usually doxo-
rubicin and cisplatin and possibly a third drug, which is 
methotrexate) used in every three-week cycles. Metho-
trexate is not widely used in adult patients with osteosar-
coma due to toxicity and lack of improvement in survival 
[20], but it is used as standard in therapeutic protocols 
in children and adolescents. It is now known that the 
escalation of CTH in the first line of treatment does not 
improve the survival and it is advisable to preserve ifos-
famide for use in the second line of treatment. Currently, 
the absence of use preoperative CTH in patients with 
Follow-up every 3–6 months 
for 5 years, then annually
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Postoperative chemotherapy
Surgical treatment — RO 
Preoperative chemotherapy — MO
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Figure 1. Diagram of the treatment for resectable osteosarcomas
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osteosarcoma should be considered a mistake. At the 
time of 4 and 5. cycle (3 weeks after the 3rd CTH cycle) 
an operation should be carried out, the aim of which is 
to radically remove the primary sarcoma. Until recently, 
the choice of the post-operative CTH regimen was based 
on the assessment of histopathological response in the 
surgical preparation (in the case of a good response, 
the treatment was continued according to the program 
initially used for 2–12 cycles, while if an unsatisfactory 
pathological response was considered, other drugs was 
considered, e.g. ifosfamide and etoposide after previous 
use of doxorubicin and cisplatin). However, the results 
of studies conducted within EURAMOS-1 showed that 
the addition of ifosfamide and etoposide to the post-
operative CTH (no benefit from intensification/change 
of treatment regimen) in patients with worse prognosis 
(no response) does not improve survival [21]. Only in 
the case of an parosteal variant of low-grade osteosar-
coma, the basis of the treatment is a radical removal of 
the lesion only. Chemotherapy is used post-operatively 
in the case of high-grade dedifferentiation in patho-
logy examination.
Muramyl tripeptide is an immunostimulant drug 
registered for adjuvant therapy in combination with 
multi-drug CTH in patients under 30 years after radical 
resection of non-metastatic osteosarcoma on the basis 
of results coming from one clinical study, which shows 
an improvement in overall survival (relative reduction 
of the risk of death by 28%, extension of six-year over-
all survival from 70% to 78%) [22] (II, C), but correct 
localisation of this drug in the therapeutic management 
requires further investigation.
Small cell sarcomas
Small cell sarcomas (mainly Ewing sarcomas, as 
well as the mesenchymal form of chondrosarcoma) are 
low-differentiated and sensitive to irradiation (used to 
treat the primary focus) and are characterised by a high 
response rate to multidrug CTH [1, 2]. They require 
long-term combination therapy (started with CTH) (I, A), 
but prognosis is worse than in spindle cell sarcomas, and 
five-year survival in adults is 30–40%, and in children 
and adolescents 56–65%. The acceptance by the patients 
of the proposed type and course of treatment together 
with all the consequences is an essential condition for 
success. Patients should be informed about the duration 
of treatment (nearly 12 months), side effects of CTH and 
RTH (direct and long distant) and functional disability 
as a result of surgical treatment (both limb-sparing and 
amputation). Considering the relatively small number 
of patients with small cell sarcomas and significant dif-
ficulties in obtaining long-term experience, it is recom-
mended to conduct treatment in oncology centres with 
extensive experience. Additional arguments are radio-
sensitivity of small cell sarcoma of bones (in contrast to 
Diagnosis
Therapeutic 
decision
Treatment
Follow-up
Follow-up every 3–6 months 
for 5 years, then annually
Physiotherapy
Postoperative/consolidation chemotherapy
Radiotherapy
Surgical treatment — RO
Preoperative chemotherapy — MO
Staging
Pathology examination
Open biopsy
Physical examination, 
additional examinations
Figure 2. Scheme of the treatment of resectable small bone 
cell sarcomas
spindle cell forms) and the important role of RTH in 
combination therapy.
Due to the chemosensitivity of small cell sarcomas, 
treatment starts with CTH (Fig. 2) regardless of the 
clinical stage (M0 or M1). Active drugs include: cyclo-
phosphamide, ifosfamide, doxorubicin, dactinomycin, 
etoposide, and vincristine (I, A) [1, 2, 6, 7, 10, 23–27]. 
The doses and schedule of individual multi-drug pro-
grams depend on the local treatment protocols and 
toxicity occurring during treatment. The inclusion of if-
osfamide and etoposide in the standard treatment (VCD 
regimen) in metastatic patients increases the duration of 
relapse-free survival and overall survival (I, A) [25]. The 
subject of a randomised trial of the third phase of Euro 
Ewing 2012, which is currently recruiting patients, is the 
comparison of the two most popular treatment programs 
(VIDE induction therapy + VAC/VAI post-operative 
treatment with the VCD/IE scheme). After inductive 
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CTH (3–5 cycles), local surgical treatment and periope-
rative RTH should be used (III, A) [10, 28–30]. If the 
size of the tumour exceeds 8 cm in the qualification and 
negative surgical margins are questionable, preoperative 
RTH or RTH and CTH should always be considered, 
which gives a chance for radical resection, and the area 
and radiation dose will be significantly lower than in 
the case of postoperative treatment (III, B). In clinical 
trials, it was not proven that irradiation of the whole 
bone was associated with an improvement of local con-
trol, and there was no significant advantage of doses 
above 60 Gy per patient survival compared to standard 
doses. RTH can be used on the initial sarcoma volume 
with a margin of 2–3 cm, which often makes it possible 
to reduce the field of irradiation and complications 
while maintaining the effectiveness of local treatment. 
It is necessary to provide a total dose of 40–60 Gy 
(depending on location) in fractions of 1.8–2.0 Gy per 
day. In the absence of radical local resection of sarco-
ma, radical RTH should be used, which — instead of 
mutilating surgery — is recommended especially for 
patients with the presence of M1 disease. In the EU-
RO-EWING99 study in patients with primary metastatic 
disease who received local treatment, the three-year 
relapse-free survival was significantly longer compared 
with those who did not receive such treatment [31]. The 
certainty of a local cure, in turn, increases the percentage 
of patients who are qualified, if necessary, for the radical 
treatment of metastases. In the case of bone tumours 
of less than 8 cm in size and with a good response to 
the initial CTH, after radical resection, it is possible to 
omit the complementary RTH. There was no phase III 
randomised trial that would compare radical RTH with 
complete resection. The results of some studies indicate 
better local control without affecting long-term survival 
after surgery with or without RTH [29, 32]. After local 
treatment, the consolidating CTH is continued until the 
maximum dose of drugs is reached (in practice at least 
six months; in total 48–52 weeks) or the onset of grade 
3 and grade 4 toxicity.
The implementation of the concept of initial combi-
nation therapy with CTH and postponed local treatment 
(Fig. 2) significantly improved long-term results of 
treatment of small cell sarcoma of bone in adults. Five-
-year survival increased from 5–10% to around 40%. 
The primary presence of metastases in distant organs 
reduces the percentage of cured patients to 30%. The 
prognosis of adult patients with small cell sarcoma is 
worse than in children due to the frequent occurrence of 
unfavourable prognostic factors, which are: metastases 
to distant organs, the longest tumour size over 8 cm 
or tumour volume above 100 cm3, age over 17 years, 
and elevated LDH activity. Worse prognosis concerns 
localisation within the pelvis and spine as well as ex-
tra-osseous forms. The patients with recurrent disease 
have particularly bad prognosis. 
In children and adolescents with Ewing sarcoma, 
the treatment includes the use of CTH according to 
the EWING 2008 schedule, and in the treatment of the 
primary focus, surgical procedures and/or irradiation. In 
the treatment of the primary focus, surgical procedures 
are recommended first. Radiotherapy is reserved for 
inoperable cases, after non-radical excision and axial 
location. Irradiation should be carried out under the 
conditions of three-dimensional RTH. This allows for 
higher doses of targeted radiation in a shorter time and 
a significant reduction in the risk of complications (dose 
of 40–60 Gy depending on the tolerance of the tissues 
affected by irradiation and age). In patients with an 
advanced process (high-risk group), high-dose CTH can 
be considered with transplantation of haematopoietic 
stem cells as part of the research protocols; this proce-
dure improves treatment outcomes in patients with risk 
factors [50]. In children in the treatment of the second 
line (progression of disease, recurrence), topotecan and 
irinotecan are used [33]. The introduction of combina-
tion therapy significantly improved the results — cur-
rently, in the case of a localised tumour, about 65% of 
patients (in children) get a cure. However, in patients 
with metastases in distant organs (lungs and/or bones) 
after CTH and surgical treatment and/or RTH, five-year 
survival is achieved in individual cases. 
In the management of patients with small cell sar-
comas there are important early complications (toxicity 
grade 3 and 4 during long-term CTH) and long-term 
ones (including — in 10% of patients secondary malig-
nancies, permanent infertility), which justifies the annual 
observation for their whole life after the treatment.
Palliative treatment
Treatment of recurrent bone sarcomas should be 
based on CTH and metastasis resection (metastasec-
tomy). In the case of lung metastases, multiple metas-
tases resections and multiple thoracotomy are often 
justified (III, B). The results of surgical treatment of 
lung metastases are quite good, provided that complete 
resection of all lesions is performed [34, 35]. The choice 
of the second-line CTH schema depends strictly on the 
drugs used in the initial treatment — often ifosfamide, 
etoposide is used (in some centres methotrexate in 
high doses with folinic acid, which concerns especially 
young patients).
Chemotherapy of patients with primary metastatic 
small cell sarcomas is based on the use of schemes 
identical to those used in the primary stage (ifosfamide 
or cyclophosphamide, doxorubicin, etoposide, and vin-
cristine). In patients with pulmonary metastases who 
achieve a complete response after CTH, irradiation 
of the entire lung volume may be considered (III, B) 
[36], and in the case of a partial response, resection of 
persistent lesions is indicated [37]. 
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As part of palliative care, RTH metastases in the 
bone play an important role.
Other primary bone tumours
The therapeutic treatment of choice in chondrosar-
coma is a radical surgical procedure without periopera-
tive treatment because in most cases (the exception is 
mesenchymal and dedifferentiated subtypes) there 
is resistance to conventional CTH and RTH. In the 
case of unresectable lesions, palliative RTH can be 
used (especially protonotherapy in skull base tumours) 
(III, B) [2, 6, 7, 10, 38]. 
Chordomas are very rare primary bone tumours 
developing usually within the sacrum or base of the 
skull. The treatment of choice is radical resection 
(rarely possible), and currently comparable results are 
obtained using proton RTH or carbon ions. Adjuvant 
RTH is indicated after R1 resection (with the margins 
occupied by the tumour in a microscopic examination) 
(III, B) [38–45]. Despite the lack of randomised trials, 
protonotherapy is the method of choice in postoperative 
therapy or as the onlytreatment in cases of unresectable 
cranial base tumours and recognised as a procedure 
guaranteed by the Polish Agency for the Evaluation of 
Medical Technology and Tariffs [46].
The giant cell tumours of bone are usually treated 
surgically, and in cases of recurrence or lack of possibil-
ity of excision, good results can be obtained using RTH 
[47]. Recent reports indicate high efficacy (> 95%) of 
anti-RANKL monoclonal antibody (denosumab) in the 
treatment of advanced giant cell tumours of bone [48] 
— denosumab is the standard treatment for unresect-
able giant cell tumours; in some patients neoadjuvant 
treatment with denosumab enables radical surgery with 
limb sparing (II, B) [49].
Rehabilitation
Rehabilitation (physiotherapy) is a necessary part of 
the management of patients with bone sarcoma because 
the beginning of treatment and is divided into:
 — preoperative CTH period — prevention of muscle 
wasting as a result of saving the affected limb (higher 
weight of healthy tissue promotes healing of the 
postoperative wound regardless of the scope of the 
operation performed, which is important in relation 
to the use of preoperative CTH);
 — postoperative period — conducting breathing and 
passive breathing exercises from the first day after 
surgery with the extension of the scope of exercises 
after removal of suction drains;
 — post-operative CTH period — use of exercises at 
home and assessment of progress during the stay in 
the ward during subsequent CTH cycles and many 
months after the end of treatment (sometimes 
periodic intensive exercises are necessary in station-
ary conditions, which results in the necessary par-
ticipation of a physiotherapist in a multidisciplinary 
diagnostic-therapeutic team).
Psychological support is important for the patient, 
the form of which is a patient support group [e.g. As-
sociation of Patients with Sarcomas “Sarcoma” (www.
sarcoma.pl), Fulfilled Dreams Foundation, Heroes 
Foundation, the Foundation for Children with Cancer, 
and others].
Follow-up after treatment
Conducting follow-up after the end of combined 
treatment is an inevitable duty of teams conducting 
radical treatment. Teams are responsible for conduct-
ing long-term observation and correct treatment of 
failures. Most relapses in patients with bone sarcoma 
occur within 2–3 years after the end of treatment, which 
justifies more frequent (every three months) follow-up 
visits [6, 7, 10]. During visits, an X-ray examination 
of the area of the operated bone and chest should be 
performed. In subsequent years, control tests may be 
less frequent (every 6–12 months). The consequence of 
intensive combination treatment of patients with bone 
sarcomas may be the occurrence of secondary tumours 
(7–10% of patients treated for small cell sarcomas). 
Other late complications of combination therapy (e.g. 
cardiovascular failure, infertility, complications of total 
hip replacement) are also important, which justifies the 
need for long-term observation of patients. The risk of 
disease relapse depends on the degree of histological 
malignancy and primary sarcoma size, the radicality of 
the combination treatment and the time from primary 
sarcoma treatment. It is known that in low-grade bone 
sarcomas less than 5 cm in size, the risk of relapse after 
radical treatment is very low, so it is often enough to 
perform an X-ray examination every 6–12 months for the 
first three years, followed by a check each year. In turn, in 
high-grade sarcomas, whose risk of lung metastases and 
local recurrence is much higher, it is necessary to perform 
cyclic chest X-ray assessment and, in addition to a care-
ful examination, imaging of the tumour area (Tab. 6).
Observation of children and adolescents with pri-
mary and malignant bone should be carried out in the 
first year every six weeks, in the second and third year, 
every three months, in the fourth year every six months, 
and from the fifth year after the end of treatment and 
in subsequent years 12 months (Tab. 7).
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Table 6. Recommended follow-up tests in adult patients with bone sarcomas
Treatment stage Examination type Frequency of tests
After radical treatment 
of sarcoma in stage 
IA–IB (with low 
histological grade 
G1/G2)
Follow up visit and physical examination every 6 months for the first 
2–3 years, then once a year
Chest X-ray — every 6–12 months, chest CT only if there are suspected 
changes in RTG
Evaluation of the place after resection by imaging (X-ray, MR, or CT) 
— regular controls every 6 months (for the first 2–3 years, then once a year)
Need to educate the patient towards self-control
Every 6 months for the 
first 2–3 years, then every 
12 months
After radical treatment 
of stage II–III sarcoma 
(higher grade G3/G4)
Follow-up and physical examination, especially of the scar of the sarcoma 
and regional lymph nodes
X-ray or chest CT 
Evaluation of the resection site by imaging (X-ray, MR, or CT) regular 
controls every 3–4 months (for the first 2–3 years, then every 6–12 months), 
for patients after radical treatment of Ewing sarcoma, bone scintigraphy 
may be considered in control 
Need to educate the patient towards self-control
Every 3–4 months for the 
first 2–3 years, then every 
6 months to 5 years after 
radical treatment, then 
once a year
After the treatment 
of distant metastases 
(grade IV)
Evaluation in imaging studies depending on the location of measurable 
metastatic foci
The follow-up visits 
scheduled for individual 
patients 
Table 7. Scheme of follow-up after treatment of primary malignant bone tumours in children and adolescents
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ECG — electrocardiography; ECHO — echocardiography; RR — arterial blood pressure; HR — heart rate; RTG — roentgenography; CT — computed tomo-
graphy; MR — magnetic resonance; USG — ultrasonography; KLP — chest; PET — positron emission tomography
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